menu
    • menu
    [{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"PPAR-gamma","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Fidaxomicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tillotts Pharma AG","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Tillotts Pharma AG","highestDevelopmentStatusID":"12","companyTruncated":"Tillotts Pharma AG \/ Tillotts Pharma AG"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Fidaxomicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tillotts Pharma AG \/ Not Applicable"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Fidaxomicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tillotts Pharma AG \/ Not Applicable"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zeria Pharmaceutical \/ CSL Vifor","highestDevelopmentStatusID":"14","companyTruncated":"Zeria Pharmaceutical \/ CSL Vifor"}]

    Find Clinical Drug Pipeline Developments & Deals by Zeria Pharmaceutical

    Menu

    Zeria Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zeria Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Zeria Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer Sorbitex Calcium

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Veltassa® (patiromer) Approved in Japan For The Treatment of Adults with Hyperkalemia

                            Details : Veltassa (patiromer sorbitex calcium) is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.

                            Brand Name : Veltassa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 23, 2024

                            Lead Product(s) : Patiromer Sorbitex Calcium

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tillotts Pharma AG

                            Switzerland arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tillotts Pharma AG

                            Switzerland arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tillotts Pharma AG Announces That Dificlirtm (fidaxomicin) Is Recommended For The Treatment Of Clostridioides ...

                            Details : DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation ...

                            Brand Name : Dificlir

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 07, 2021

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tillotts Pharma AG

                            Switzerland arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tillotts Pharma AG

                            Switzerland arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg

                            Details : Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.

                            Brand Name : Dificlir

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 20, 2021

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tillotts Pharma AG

                            Switzerland arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tillotts Pharma AG

                            Switzerland arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Astellas Pharma

                            Deal Size : $130.3 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Astellas Transfers Dificlir in Europe, Middle East, Africa and selected CIS to Tillotts Pharma

                            Details : Under the agreement, Astellas Europe will transfer its marketing authorizations for Dificlirtm (generic name: fidaxomicin) tablets for Clostridium difficile infections in Europe, Middle East, Africa and selected Commonwealth of Independent States to Till...

                            Brand Name : Dificlir

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 27, 2020

                            Lead Product(s) : Fidaxomicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Astellas Pharma

                            Deal Size : $130.3 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zeria Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Zeria Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical

                            Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 03, 2020

                            Lead Product(s) : Mesalazine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth